Trials / Unknown
UnknownNCT02914158
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen for Hormone Receptor-Positive Breast Cancer in Women Younger Than 35: A Multicenter Randomized Clinical Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 680 (estimated)
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to compare the curative effects in patients under the age of 35 with hormone receptor positive breast cancer and high recurrent risk factors including large tumor or metastatic lymph nodes randomized to ovarian function suppression (OFS) plus aromatase inhibitors or OFS plus tamoxifen as adjuvant endocrine therapy, and explore the differences of curative effects between different subtypes to provide direct evidence for treatments of young breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Goserelin | |
| DRUG | Tamoxifen | |
| DRUG | Aromatase Inhibitors | |
| DRUG | Leuprolide |
Timeline
- Start date
- 2016-03-30
- Primary completion
- 2023-12-30
- Completion
- 2025-12-01
- First posted
- 2016-09-26
- Last updated
- 2023-01-17
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02914158. Inclusion in this directory is not an endorsement.